IP Library Granted Patent US 9,283,265
Granted Patent B2
US 9,283,265 · App. 14/507,648 · Granted Mar 15, 2016

DNA vaccines encoding heat shock proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,265
App. No.
14/507,648
Granted
Mar 15, 2016
Kind
B2
Abstract

A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.

Claims (19)

1. A method of treating inflammatory bowel disease in an individual, the method comprising:

administering by intramuscular injection to an individual having an inflammatory bowel disease a composition comprising a nucleic acid molecule encoding a mammalian heat shock protein 90 (HSP90), or an active fragment thereof, in an amount effective to provide for a shift to a Th2 immune response in the individual, wherein the nucleic acid molecule is operatively linked to one or more transcription control sequences,

wherein the administering treats the inflammatory bowel disease in the individual.

2. The method of claim 1 , wherein the composition comprises a delivery vehicle selected from the group consisting of liposomes, micelles, and emulsions.

3. The method of claim 1 , wherein the composition comprises about 0.1 μg/kg body weight to about 200 μg/kg body weight of the nucleic acid molecule encoding the mammalian HSP90, or an active fragment thereof.

4. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.

5. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.

6. The method of claim 1 , wherein the mammalian HSP 90 is human HSP90.

7. The method of claim 1 , wherein the individual is a human.

8. The method of claim 1 , wherein the composition comprises about 0.1 μg/kg body weight to about 10 μg/kg body weight of the nucleic acid molecule encoding the mammalian HSP90, or an active fragment thereof.

9. A method of treating inflammatory bowel disease in an individual, the method comprising:

administering by intramuscular injection to an individual having an inflammatory bowel disease a composition comprising about 0.1 μg/kg body weight to about 200 μg/kg body weight of a nucleic acid molecule encoding mammalian heat shock protein HSP90, wherein the nucleic acid molecule is operatively linked to one or more transcription control sequences,

wherein the administering treats the inflammatory bowel disease in the individual.

10. The method of claim 9 , wherein the composition comprises about 0.1 μg/kg body weight to about 10 μg/kg body weight of the nucleic acid molecule encoding the mammalian HSP90.

11. The method of claim 9 , wherein the inflammatory bowel disease is Crohn's disease.

12. The method of claim 9 , wherein the composition comprises a delivery vehicle selected from the group consisting of liposomes, micelles, and emulsions.

13. The method of claim 9 , wherein the inflammatory bowel disease is ulcerative colitis.

14. The method of claim 9 , wherein the HSP90 is human HSP90.

15. The method of claim 9 , wherein the individual is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: COHEN, IRUN R.; QUINTANA, FRANCISCO J.; CARMI, PNINA; MOR, FELIX
To: ALMA BIO THERAPEUTICS
Reel/Frame 036844/0250 →